Tempest Therapeutics Inc (FRA:3OS)
€ 0.704 0 (0%) Market Cap: 35.42 Mil Enterprise Value: 31.23 Mil PE Ratio: 0 PB Ratio: 2.05 GF Score: 39/100

Tempest Therapeutics Inc To Discuss Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Call Transcript

Oct 11, 2023 / 12:30PM GMT
Release Date Price: €5.95 (+3339.31%)
Operator

Good morning, and thank you all for joining the Tempest Therapeutics conference call. At this time, all participants are in listen-only mode. As a reminder, today's conference call is being recorded. Following management's remarks, we will hold a question-and-answer session, and at that time, the lines will be open.

I would now like to turn the call over to Aljanae Reynolds. Please go ahead.

Aljanae Reynolds
Wheelhouse Life Science Advisors - IR

Thank you, operator, and good morning, everyone. Thank you for joining our call to discuss the new positive data from the global randomized trial of TPST-1120 in first-line liver cancer. For your reference, a press release covering the news is available on the company's website at tempesttx.com.

Joining me on the call today are Steve Brady, President and Chief Executive Officer; and Dr. Sam Whiting, Chief Medical Officer and Head of Research and Development.

Turning to slide 2. During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot